In a recent comprehensive review published in Cyborg Bionic Systems, researchers led by Keyi Li from the General Hospital of Northern Theater Command in Shenyang, along with international collaborators, detail significant advances in the identification and application of biomarkers for prostate cancer (PCa). This critical insight is pivotal as prostate cancer remains one of the most common malignancies among men globally, emphasizing the urgent need for effective diagnostic and therapeutic strategies. Prostate cancer is characterized by a multitude of molecular aberrations that complicate its early detection and treatment.
The review discusses various biomarkers across molecular, cellular, and exosomal categories, showcasing their potential to revolutionize how prostate cancer is diagnosed and treated. One of the major highlights of the review is the discussion on gene fusions like TMPRSS2-ERG, which are prevalent in prostate cancer and serve as vital diagnostic indices. The presence of noncoding RNAs such as SNHG12 and proteins like PSA and PSMA also hold substantial promise in not only detecting the disease but also in understanding its progression and guiding therapy.
In terms of technological integration, the review illuminates the growing role of multi-omics data and artificial intelligence in prostate cancer research. These technologies contribute significantly to the biomarker discovery process, enhancing the ability to tailor personalized medicine approaches for patie.